$7.260
+0.112 (+1.54%)Zum Schluss
IMTX-News
IMTX-Events
Immatics Updates Clinical Trial Data for IMA402 and IMA203CD8
Immatics announced updated clinical trial data from its ongoing Phase 1b study with IMA402 PRAME bispecific and its Phase 1 study with IMA203CD8 PRAME cell therapy. Key highlights: IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile; IMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of 91% in advanced melanoma patients with high PRAME expression; Clinical profile of IMA402 reinforces development path across multiple solid tumor indications, including melanoma, gynecologic cancers and lung cancer, in earlier and later treatment lines, supported by Immatics' innovative, rapid liquid biopsy-based PRAME testing; IMA203CD8 PRAME cell therapy demonstrated deep and durable anti-tumor activity across multiple tumor types with a manageable safety profile, supporting its tumor-agnostic potential. At clinically relevant dose levels in patients with advanced, heavily pretreated gynecologic cancers, cORR was 55% with a median DOR of 8.4 months
Immatics N.V. to Sell 12,945,916 Shares at $8.69 Each
Immatics N.V. announced that it has agreed to sell 12,945,916 ordinary shares at $8.69 per share and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 4,315,304 ordinary shares at a purchase price of $8.689 per pre-funded warrant, which represents the per share offering price less the $0.001 per share exercise price for each pre-funded warrant, in an underwritten offering. The gross proceeds from the offering, before deducting the underwriting discount and offering expenses, are expected to be $150 million. The offering is expected to close on August 26, 2026, subject to customary closing conditions. In addition, Immatics has granted the underwriters a 30-day option to purchase up to 2,589,184 additional shares at the public offering price, less the underwriting discount. Jefferies, Leerink Partners and Cantor are acting as joint book-running managers for the offering.
Stock Futures Weaken as Oil Prices and Treasury Yields Rise
Stock futures are pointing to a weaker open as fading hopes for a U.S.-Iran peace agreement push oil prices and Treasury yields higher. Brent crude is rising as the ceasefire between the U.S. and Iran comes under pressure, while the 30-year Treasury yield has climbed to around 5.33%, its highest level since 2007. The combination of higher oil and long-term yields is tightening financial conditions and making high-duration technology stocks particularly vulnerable.AI and semiconductor stocks are bearing the brunt of the selling. The weakness comes as investors reassess elevated valuations across the AI trade, with higher borrowing costs adding another headwind to companies whose valuations depend heavily on future growth.The retail sector is providing some support. Home Depot is gaining about 2% after reporting second-quarter sales above expectations, although the company said the housing market remains challenging. Investors will also look to Target and Walmart later this week for a clearer picture of consumer spending and the health of the U.S. consumer.The Federal Reserve's July meeting minutes, due Wednesday, are another catalyst. After the recent weak labor-market data and relatively benign inflation reports, investors have been looking for evidence that policymakers are becoming more comfortable with eventual rate cuts. However, the renewed rise in oil prices and long-term Treasury yields could complicate that outlook.In pre-market trading, S&P 500 futures fell 0.52%, Nasdaq futures fell 0.3% and Dow futures fell 0.10%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Amylyxup 36% after its Lucidity trial met the FDA-agreed-upon primary endpoint demonstrating a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placeboUP AFTER EARNINGS -Duos Technologiesup 11%Flexsteel Industriesup 6%Home Depotup 2%Amer Sportsup 8%DOWN AFTER EARNINGS -Klarnadown 20%Fabrinetdown 11%Baidudown 9%VNET Groupdown 8%Immaticsdown 2%Pony AIdown 3%LOWER -XTI Aerospacedown 7% after announcing Scott Pomeroy has resigned as CEO and that the company is delaying its quarterly report to complete an internal reviewTesladown 2% after The Informationthe company has told staff it is planning for a public Cybercab launch in August
Immatics Presents IMA401 Clinical Trial Data at ASCO Meeting
Immatics announced the presentation of extended data from the ongoing Phase 1 clinical trial evaluating its TCR bispecific candidate IMA401 targeting MAGEA4/8 in heavily pretreated patients with solid tumors, including head and neck cancer and lung cancer, in an oral presentation at the Annual Meeting of the American Society for Clinical Oncology, ASCO, in Chicago, IL, USA. Results from the Phase 1 study are being published simultaneously in Nature Medicine. Key data: IMA401 achieved deep and durable responses in various indications, including melanoma and head and neck cancer, with an initial promising clinical signal observed in lung cancer; In head and neck cancer, IMA401 treatment at recommended Phase 2 dose with or without pembrolizumab resulted in a 29% confirmed ORR, 64% DCR and mDOR of 8.8 months; all responders achieved deep responses with 60-100% tumor reduction; IMA401 MAGEA4/8 TCR bispecific demonstrated favorable tolerability at RP2D with or without pembrolizumab, suggesting its potential for broad combinability; IMA401 data will be presented in an oral presentation at the 2026 ASCO Annual Meeting and published simultaneously in Nature Medicine; The data support Immatics' strategy to combine IMA401 with IMA402 in lung cancer and potentially other indications, where the combined target prevalence supports broad patient coverage and potential synergistic activity; the IMA401/IMA402 combination cohort is now enrolling at multiple clinical trial sites, with first data expected in 2027
Immatics Updates Phase 1 Data for IMA203CD8 Therapy
Immatics N.V. announced updated Phase 1 data for its IMA203CD8 PrameTCR T-cell therapy in gynecologic cancers and synovial sarcoma at the Annual Meeting of the American Society for Clinical Oncology, ASCO, in Chicago, IL, USA. One-time infusion of IMA203CD8 demonstrated meaningful clinical activity across different tumor types as well as manageable tolerability. The broad expression of PRAME in more than 50 cancers further supports the continued development of IMA203CD8 in multiple PRAME-positive solid tumors. IMA203CD8 demonstrated a manageable and consistent tolerability profile across patient populations. Clinical anti-tumor activity observed across tumor types with distinct biology and differing levels of PRAME expression, including lower PRAME levels in ovarian carcinoma. Clinical profile of IMA203CD8 supports continued development in gynecologic cancers and expansion into other PRAME-positive solid tumors. Determination of recommended phase 2 dose remains expected in 2026
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.